HER2-Positive Breast Cancer Market Trends

Human epidermal growth factor receptor 2 (HER2) is a gene that is linked to breast cancer development. Genes contain the recipes for numerous proteins required by a cell to remain healthy and function normally. This protein stimulates cancer cell proliferation. Cancer cells in around one out of every five breast tumors have extra copies of the gene that produces the HER2 protein. Breast cancers that are HER2-positive are more aggressive than other kinds of breast cancer. Although anticancer medications do not directly target the HER2 protein, certain regular chemotherapy treatments can be useful in treating HER2-positive breast tumors. Experts advise testing for the presence of HER2 in all invasive breast cancers since the results have a substantial impact on treatment recommendations and decisions. Except as part of a clinical trial, HER2 testing is not typically performed for ductal carcinoma in situ. When breast cancer recurs or expands, the cancer cells should be retested for HER2 and hormone receptor status, as these can alter after the original diagnosis.

COVID-19 Impact Analysis:

Pharmaceutical and biotech companies together with governments globally are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, about 115 vaccine samples and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the rise in the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the HER2-positive breast cancer market.

Top Impacting Factors:

Factors that drive the growth of the HER2-positive breast cancer market include the increase in HER2-positive breast cancer cases globally, which is expected to affect the demand for innovative medications for HER2-positive breast cancer therapy.
Furthermore, strong immunotherapy adoption and favorable reimbursement are viewed as good indicators for the growth of the HER2-positive breast cancer market.
The rise in awareness of HER2-positive breast cancer, as well as the increase in healthcare spending globally, is expected to drive the market expansion.
Major firms are participating in the development of medicines for HER2-positive breast cancer and the introduction of new medications are anticipated to have a substantial impact on the HER2-positive breast cancer market.
A surge in R&D activities by leading companies to introduce an approved and effective treatment for HER2-positive breast cancer is expected to act as a market driver.
However, the market for HER2-positive breast cancer is expected to be severely hampered by high treatment costs combined with the discontinuation of late-stage clinical trials.

Market Trends:

New Product Launches to Flourish HER2-Positive Breast Cancer Market

In May 2019, the Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (KADCYLA, Genentech, Inc.) for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) who have the residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.

Key Benefits of Report:

This study presents the analytical depiction of the HER2-positive breast cancer along with the current trends and future estimations to determine the imminent investment pockets.
The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the HER2-positive breast cancer market share.
The current market is quantitatively analyzed to highlight the HER2-positive breast cancer market growth scenario.
Porter’s five forces analysis illustrates the potency of buyers & suppliers in the HER2-positive breast cancer market.
The report provides a detailed HER2-positive breast cancer market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the HER2-Positive Breast Cancer Market Report:

Who are the leading market players active in the HER2-positive breast cancer market?
What current trends will influence the HER2-positive breast cancer market in the next few years?
What are the driving factors, restraints, and opportunities in the HER2-positive breast cancer market?
What future projections would help in taking further strategic steps?
What is HER2-positive breast cancer?
What is HER2-positive breast cancer market prediction for the future?
Who are the leading global players in the HER2-positive breast cancer market?
What are the current trends and predicted trends?
What are the key benefits of the HER2-positive breast cancer market report?

HER2-Positive Breast Cancer Market Report Highlights

Aspects	Details
By Treatment Type	Chemotherapy Targeted Therapy Immunotherapy Others
By Route of Administration	Oral Parenteral Others
By End User	Hospitals Homecare Specialty Clinics Others
By Distribution Channel	Hospital Pharmacy Online Pharmacy Retail Pharmacy
By Region	North America (U.S., Canada, Mexico) Europe (Germany, France, UK, Italy, Spain, Rest of Europe) Asia-Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific) LAMEA (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players	Mylan N.V., Merck & Co., Inc., Teva Pharmaceuticals Industries Ltd., Eli Lilly and Company, GlaxoSmithKline plc., Pfizer Inc., AstraZeneca, Takeda Pharmaceutical Company Limited, Bayer AG, Fresenius Kabi AG, Novartis AG, Baxter, F. Hoffmann-La Roche Ltd.